Biologics Contract Development And Manufacturing Organization (CDMO) Market - Strategic Insights and Forecasts (2026-2031)

Biologics Contract Development and Manufacturing Organizations (CDMOs) provide development and manufacturing services for biological medical products in the pharmaceutical industry. They support pharmaceutical and biotechnology companies across cell-line development, process development, analytical testing, formulation, clinical manufacturing, commercial manufacturing, and fill-finish. Biologics, also known as biopharmaceuticals, are medical products developed from living organisms or their components. According to the US Food and Drug Administration, biological products include vaccines, blood components, recombinant proteins, gene therapies, cells, tissues, and other complex products. Biologics CDMOs mainly work with large-molecule products, although some diversified CDMOs also offer small-molecule and specialised formulation services.

There are various companies operating in the biologics CDMO market. Ascendia Pharmaceuticals provides formulation and drug-delivery services for difficult-to-formulate compounds. Its work covers selected biologic and small-molecule programmes rather than the full large-scale biologics manufacturing model associated with companies such as Lonza, WuXi Biologics, Samsung Biologics, and FUJIFILM Biotechnologies. Some of Ascendia's well-known formulation technologies include EmulSol®, NanoSol®, and AmorSol®.

The global biologics CDMO market is expected to witness significant growth during the forecasted period of 2026-2031, due to factors such as increased investments in pharmaceutical research and development. The market is also being driven by the growth of monoclonal antibodies, recombinant proteins, vaccines, biosimilars, and more complex biologic modalities that require specialised development and manufacturing facilities.

A biologics contract development and manufacturing organization may support a product from early process design through clinical supply and commercial production. This distinguishes a CDMO from a contract manufacturing organization (CMO), which is generally more focused on manufacturing an established process, and from a contract research organization (CRO), which mainly supports research and clinical-development activities. In practice, the boundaries can overlap, particularly among large integrated providers.

Biologics CDMO Services:

Carbohydrate CDMO services form a more specialised part of the wider outsourcing market. They may involve complex sugars, polysaccharides, glycoconjugates, or carbohydrate-based vaccine components. These services require specific synthesis, purification, characterisation, and conjugation capabilities and should not be treated as interchangeable with mainstream mammalian biologics manufacturing.

Market Drivers:

• Increasing investments in pharmaceutical R&D: The increasing investments in the R&D of biopharmaceuticals support the growth of biologics in the pharmaceutical industry, driving demand for CDMO capacity and expertise. Biologics CDMOs are known for their specialisation in the development and manufacturing of biologics and provide services that may be difficult or expensive for pharmaceutical companies to build internally. Outsourcing allows a sponsor to access specialist scientists, validated facilities, quality systems, and manufacturing capacity without constructing a dedicated plant for every development programme.

Drug development remains costly and uncertain, particularly before clinical efficacy and commercial demand are established. This encourages biotechnology companies to use external capacity for early development and clinical supply. Larger pharmaceutical companies also use biologics contract manufacturing to add capacity, support product launches, manage supply risk, and transfer products between regions.

• Prevalence of chronic diseases: The increasing prevalence of chronic diseases drives demand for improved treatments, including monoclonal antibodies and other biologic medicines. According to the World Health Organization, noncommunicable diseases caused at least 43 million deaths in 2021, representing 75% of non-pandemic-related deaths globally. Cancer, cardiovascular disease, diabetes, chronic respiratory disease, and autoimmune conditions support long-term demand for targeted therapies. Disease prevalence does not translate directly into CDMO revenue, but it supports the clinical and commercial biologics pipeline served by contract manufacturers.

• Complex biologics and biosimilars: Bispecific antibodies, antibody-drug conjugates, high-concentration formulations, recombinant proteins, and biosimilars create additional process and analytical requirements. Biosimilar CDMOs must support process development, analytical comparability, scale-up, regulatory documentation, and cost-efficient commercial production.

• Need for flexible capacity: Clinical programmes require flexible production and rapid scheduling, whereas approved products may require large-volume commercial supply. CDMOs that can move a programme from development to commercial manufacturing reduce the need for repeated technology transfers and may improve continuity across the product lifecycle.

Key Players:

• WuXi Biologics: A global leader operating as a Contract Research, Development and Manufacturing Organization (CRDMO), offering end-to-end solutions that enable partners to discover, develop, and manufacture biologics. The company provides cell-line, process, analytical, clinical, and commercial manufacturing services across multiple biologic modalities.

• Lonza: A Swiss multinational company known for its specialisation in pharmaceuticals and biotechnology. Its Integrated Biologics offering covers drug-substance and drug-product development from preclinical work through commercialisation.

• Samsung Biologics: A global biologics CDMO offering development, mammalian drug-substance manufacturing, and aseptic fill-finish. Its services cover cell-line development, process development, analytical work, clinical manufacturing, and commercial-scale supply.

• FUJIFILM Biotechnologies: A biologics, vaccines, and advanced-therapies CDMO with mammalian, microbial, and drug-product manufacturing capabilities. Its network includes facilities in the United States, the United Kingdom, Denmark, and Japan.

• Boehringer Ingelheim BioXcellence: A biologics contract manufacturer working with both mammalian cell culture and microbial systems. Its BioXcellence network supports clinical and commercial biopharmaceutical manufacturing.

Other biologics CDMO companies include Thermo Fisher Scientific's Patheon business, Catalent operations retained outside the Novo Nordisk transaction, AGC Biologics, KBI Biopharma, Rentschler Biopharma, and several regional providers. Company selection should depend on technical fit, regulatory history, available scale, geographic supply requirements, and the stage of the product rather than company size alone.

Regional Analysis:

North America and Europe remain major markets for biologics contract development and manufacturing because they contain large pharmaceutical pipelines, experienced workforces, regulatory expertise, and substantial clinical and commercial capacity. The United States is particularly important for biotechnology funding, early development, and commercial demand, while Europe has established biologics clusters in Switzerland, Germany, the United Kingdom, Ireland, Denmark, and other countries.

The Asia Pacific region is expected to witness significant growth in the biologics CDMO market during the forecast period. China and India are expected to contribute to regional growth due to the expansion of their biotechnology and pharmaceutical industries. South Korea and Singapore are also important manufacturing locations, supported by large-scale capacity, established quality systems, and investment by global and regional providers.

According to official Indian government information, India's bioeconomy reached US$165.7 billion in 2024 and is targeted to exceed US$300 billion by 2030. The wider bioeconomy includes biopharmaceuticals, agriculture biotechnology, industrial biotechnology, research services, and other activities. For biologics CDMOs, the most relevant Indian opportunities are vaccines, biosimilars, recombinant proteins, analytical development, and clinical-to-commercial manufacturing services.

China has developed a broad biologics services base, South Korea has added substantial mammalian manufacturing capacity, and Singapore remains a regional site for multinational biopharmaceutical production. Asia Pacific growth is therefore expected to come from several specialised manufacturing clusters rather than from China and India alone.

Market Developments:

• March 2026: WuXi Biologics reported its 2025 annual results, including 74 Phase III projects and 25 commercial manufacturing projects. The company completed 28 process performance qualification campaigns during the year.

• January 2026: Samsung Biologics reported plans to acquire a US manufacturing site in Rockville, Maryland. The site includes two CGMP drug-substance plants with combined capacity of 60,000 litres, expanding the company's manufacturing presence outside South Korea.

• September 2025: FUJIFILM Biotechnologies opened its Holly Springs, North Carolina site. The first phase includes eight 20,000-litre mammalian cell-culture bioreactors and co-located drug-product capabilities.

• April 2025: Samsung Biologics added 180,000 litres of capacity through Plant 5, increasing its ability to support large-scale mammalian biologics programmes.

• January 2024: EXO Biologics announced the launch of ExoXpert, a CDMO offering exosome development and manufacturing services. The platform supports MSC-based exosome production used in European clinical trials.

• October 2023: Tanvex BioPharma USA Inc. announced the launch of Tanvex CDMO, providing biologic contract development and manufacturing services to biopharmaceutical companies.

How Companies Select a Biologics CDMO:

Biotechnology and pharmaceutical companies generally assess a biologics CDMO on technical capability, quality history, regulatory inspection experience, available capacity, cost, project-management strength, and supply-chain resilience. A mammalian antibody program may require different facilities from a microbial protein, carbohydrate conjugate, vaccine, or biosimilar program. Sponsors also examine whether the provider can support both drug substance and drug product, experience at the required batch scale, and capacity availability.

Technology transfer is another important consideration as moving a process between laboratories, manufacturing scales, or sites can create delays and comparability work. An integrated biologics development and manufacturing provider may reduce the number of transfers, but a multi-CDMO strategy can provide supply diversification. The preferred approach depends on the product's complexity, commercial value, launch schedule, and supply-risk tolerance.

Biologics Contract Development And Manufacturing Organization (CDMO) Market Scope